Assenagon Asset Management S.A. lessened its holdings in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) by 40.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 84,272 shares of the company’s stock after selling 58,156 shares during the period. Assenagon Asset Management S.A. owned approximately 0.19% of Cardiff Oncology worth $117,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Walleye Capital LLC bought a new position in shares of Cardiff Oncology during the 1st quarter valued at about $306,000. Bank of America Corp DE lifted its holdings in shares of Cardiff Oncology by 145.0% during the 1st quarter. Bank of America Corp DE now owns 79,918 shares of the company’s stock valued at $132,000 after purchasing an additional 47,297 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Cardiff Oncology by 69.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 36,500 shares of the company’s stock valued at $80,000 after purchasing an additional 15,020 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Cardiff Oncology during the 1st quarter valued at about $62,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Cardiff Oncology by 116.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 40,163 shares of the company’s stock valued at $62,000 after purchasing an additional 21,632 shares in the last quarter. Institutional investors own 13.42% of the company’s stock.
Insider Buying and Selling at Cardiff Oncology
In other news, Director Gary W. Pace bought 30,000 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were purchased at an average price of $1.37 per share, for a total transaction of $41,100.00. Following the purchase, the director now owns 697,761 shares of the company’s stock, valued at approximately $955,932.57. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 6.30% of the company’s stock.
Cardiff Oncology Stock Performance
About Cardiff Oncology
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
- Five stocks we like better than Cardiff Oncology
- How to Invest in Biotech Stocks
- The 5 best small cap AI companies to buy now
- Insider Trading – What You Need to Know
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- What is a Low P/E Ratio and What Does it Tell Investors?
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.